CEOs of GlaxoSmithKline tapping their R&D investments in Korea

Published: 2002-05-10 06:56:00

Updated: 2002-05-10 06:56:00

The chief executive officers of GlaxoSmithKline in U.K. have made their frequent visits to Korea to tap the possibility of promoting business collaboration with the Korean counterpart in the domestic bioindustry arena.

Chairman Robert A. Ingram was the first visitor to Korea last March, follo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK